AML3D (ASX:AL3) Reports $16.8 Million Order Book and $24.42 Million Cash After September Quarter

Sonal Goyal

23 October 2026 06:52 PM AEDT

AML3D (ASX:AL3) Reports $16.8 Million Order Book and $24.42 Million Cash After September Quarter

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Orders of $16.8 million rolled into FY27, against $9 million into FY26, and the global sales pipeline exceeds $80 million.
Customer receipts for the September 2026 quarter were $3.0 million, up 19% on the prior comparable period.
A $9.9 million order for four ARCEMY X systems from Newport News Shipbuilding is tracking for delivery in the second quarter.
Cash stood at $24.42 million on 30 September 2026, equal to 11 estimated quarters of funding at the current operating outflow.

AML3D Limited (ASX:AL3) released its quarterly activities report and Appendix 4C on 23 October 2026 for the quarter ended 30 September 2026, the first quarter of FY27. The company said its focus was progressing the $16.8 million of orders that rolled into FY27, an 87% increase on the $9 million that rolled into FY26, while its global sales pipeline now exceeds $80 million.

Orders and Delivery in the United States

AML3D described its US scale-up as the primary growth driver, with its Stow, Ohio, technology centre focused on the rolled-over orders. The largest is a $9.9 million contract from Newport News Shipbuilding for four large-scale ARCEMY X systems, which the company said doubles that customer's previous order and is tracking for delivery in the second quarter of FY27.

The company also announced a first US nuclear submarine industrial base production parts order from Austal USA Advanced Technologies, valued at about AU$0.5 million, for three high-pressure fluid control components. A separate order from BlueForge Alliance for five non-safety-critical replacement components is already in production. These orders, together with a $2.61 million in-service trial order, are tracking for third-quarter delivery.

Quarter Financials

Cash receipts were $3.0 million, against $2.5 million in the prior comparable period. Product manufacturing and operating costs rose 200% to $2.5 million from $0.76 million, which the company attributed to higher order volumes. Net cash used in operating activities was $2.13 million, up from $0.59 million.

Cash and cash equivalents closed at $24.42 million, down from $26.67 million at the start of the quarter, comprising $4.42 million in bank balances and $20 million in call deposits. The Appendix 4C reports no financing facilities.

Why This Could Matter

The company said the growing value and volume of ARCEMY orders and the move toward production parts for the US Navy support its $12 million investment to double US manufacturing capacity. It has also pre-allocated $5 million for a new technology centre to serve the UK, Europe, the Middle East and Southeast Asia, with the location to depend on emerging demand. AML3D said this is expected to reduce lead times on European defence and industrial contracts as they emerge.

In Australia, AML3D has joined a global aerospace prime and research partners in a three-year, $3.9 million R&D project, contributing about $0.5 million, of which $130,000 is cash. The company said the project is not expected to generate revenue directly.

The Quarter in Summary

AML3D reported higher receipts, a larger order book and a lower cash balance than at the start of the quarter, while continuing a funded programme to double US capacity and establish a new technology centre.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.